Kenvue received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. The approval adds a differentiated option to Kenvue's Self Care portfolio and could strengthen the Tylenol brand's position in the competitive pain relief category. The company's upcoming second quarter 2026 results on August 6, 2026, will provide an updated view on Self Care performance and how quickly new launches like Tylenol with Naproxen contribute alongside existing brands. Kenvue's investment narrative projects $16.7 billion revenue and $2.3 billion earnings by 2029, with a fair value estimate of $19.50 per share. Community valuations for Kenvue range from $19.50 to $32.38 per share, reflecting divergent expectations about the impact of new products on the company's growth trajectory.
Kenvue Inc.FDA approval for Tylenol with Naproxen adds a new OTC product to Kenvue's portfolio.